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Abstract
Introduction: The use of naloxone to reverse a potentially fatal opioid overdose is a harm reduction strategy
that reduces mortality and increases the potential for referral to substance use treatment for affected
individuals. In the setting of outreach performed by a street medicine team, we aimed to determine the
effectiveness of an educational intervention involving distribution of naloxone accompanied by a brief
instructive session about opioids, opioid overdose, and medication administration.
Methods: Our street medicine outreach team distributed 200 naloxone kits to clinicians and volunteers
involved in caring for patients on ‘street rounds,’ as well as in shelters, soup kitchens, and street medicine
clinic settings. Those receiving a naloxone kit engaged in a peer-reviewed presentation on how to safely use
the medication to reverse a potentially fatal opioid overdose. The study team developed and administered a
pre- and post-survey of 10 multiple choice questions on material covered in the educational training. The
pre- and post-survey scores were compared to assess the effectiveness of implementing this training. Results
were stratified by participant gender and age group.
Results: Out of the 200 participants, six were excluded from the analysis due to completely missing data from
one or both surveys. The mean age of participants was 40.2±12.5 years; 120 (65.6%) were female, 62 (33.9%)
were male, and 1 (0.6%) identified as nonbinary. Every survey question had an increase in correct responses
from pre-survey to post-survey (identified by an increase in the percentage of correct responses). The mean
survey total score increased from 5.5±1.6 to 7.5±1.3. Within the sample of 194, the mean difference in scores
from pre-survey to post-survey was 2.02 points (95% CI [1.77, 2.26]), p<0.0001. Males had a mean increase in
the total score from 5.6±1.8 to 7.4±1.1. Females had a mean increase in the total score from 5.5±1.5 to
7.5±1.3. The difference in total scores in males was 1.89 points (95% CI [1.42, 2.35]), p<0.0001, and in
females was 2.02 points (95% CI [1.71, 2.32]), p<0.0001. Post-test scores improved in all age groups.
Conclusion: The educational training on opioids, opioid overdose, and the use of naloxone was an effective
adjunct to naloxone kit distribution to volunteers and clinicians caring for people experiencing
homelessness.
Categories: Emergency Medicine, Substance Use and Addiction
Keywords: opioid epidemic, community education, underserved populations, harm reduction, street medicine,
naloxone
Introduction
In the new millennium, there have already been nearly 500,000 deaths related to opioid overdose [1]. While
multifactorial, the opioid overdose crisis likely began with the over-prescribing of opioids in the late 1990s.
Subsequent studies demonstrated that most heroin users in the early 2000s initiated their opioid use
trajectory with prescription opioids [2,3]. As people with opioid use conditions transitioned to street
opioids, and as powerful synthetic opioids became more prolific within that street supply, the rate of fatal
overdose rose from 1:100,000 in 2013 to nearly 9:100,000 in 2018, with some states reporting high-potency
fentanyl detected in greater than 50% of all overdose-related deaths [1,4].
Despite being invented in 1961, naloxone was uncommonly prescribed until the 1990s, and even then, it was
relegated to intravenous use until 2014 [5]. Once intramuscular and intranasal formulations became
available, studies showed similar bio-availability, time to symptom reversal, and efficacy for intranasal
formulations versus intravascular or intramuscular delivery [5-8]. Emergency medical services (EMS)
professionals equipped with intranasal naloxone have achieved reversal in greater than 98% of cases of
suspected or known opioid overdose [6,9]. Concerns have been raised about the use of naloxone in patients
who have used long-acting opioids, who may be at higher risk of morbidity and mortality after receiving
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naloxone. However, a study of 552 patients who received naloxone in the field for suspected overdose found
no reported fatalities among this group in the 48 hours after treatment [10].
Underutilization of naloxone may be in part due to stigma over its possession, lack of availability, as well as
variability among state laws regarding layperson distribution [11-13]. In states in which naloxone
availability is mandated at pharmacies, it has been found that locations in neighborhoods with lower
socioeconomic status reported either lower quantity or no stock at all, potentially contributing to a lack of
access in these environments [12]. Vulnerable populations in urban neighborhoods as well as communities
with high rates of homelessness have reported fear of punitive legal action if naloxone is used and
emergency services are activated [13].
Lack of education regarding the effects of naloxone in acute opioid overdose may further contribute to
hesitation among bystanders to carry and use naloxone. Though there have been case descriptions of non-
cardiogenic pulmonary edema and life-threatening dysrhythmias, the overall reported incidence of these
events has been as low as 1%, with all occurrences being associated with intravenous administration
[14,15]. The primary end point of titration for naloxone dosing is decreased respiratory depression; however,
there may be a lay misconception that resolution of sedation is the true goal of therapy, resulting in the
administration of unnecessary additional doses of naloxone that can lead to severe withdrawal
symptoms. Given these concerns, it is likely that more widely available and standardized community
education programs could lead to more appropriate naloxone use.
One study found that 5%-16% of patients presenting to an emergency department for medical care were
experiencing homelessness [16]. According to the Substance Abuse and Mental Health Services
Administration, the estimated rate of substance use disorder among persons experiencing homelessness is
26%-38% [17]. Due to the stigma surrounding both substance use disorder and homelessness, it is imperative
to ensure the clinicians who serve stigmatized populations have access to naloxone and education on how to
use this medication.
For community members with stigmatizing conditions such as lack of shelter and substance use disorder,
mobile access to care including high-cost lifesaving medications, such as naloxone, may help save lives and
ensure patients have access to the care they deserve. At our institution, the street medicine team practices a
model that focuses on delivering care wherever persons with homelessness feel most comfortable, including
providing access to naloxone during episodes of care in shelters, soup kitchens, and in encampments. In the
setting of outreach performed by a street medicine team, we set out to determine the effectiveness of a brief
educational intervention involving the distribution of naloxone accompanied by education on opioids,
opioid overdose, and how to administer the medication.
Naloxone training programs have been shown to be effective in improving knowledge around overdose
recognition and the use of naloxone [18]. Overdose education and naloxone distribution programs improve
self-efficacy surrounding overdose prevention and response for up to 12 months following a brief training
[19]. Training first responders and other clinicians with a brief training can improve their perceptions and
comfort with overdose and naloxone use [20].
We hypothesized that providing naloxone kits and accompanying education to street medicine outreach
clinicians and volunteer ‘first responders’ would increase knowledge around opioids, opioid overdose, and
how naloxone is used, as measured by pre- and post-education testing.
Abstract presentations describing this initiative were presented in virtual format at the Pennsylvania
American College of Emergency Physicians meeting on April 9, 2021, and at the Society for Academic
Emergency Medicine meeting on May 13, 2021.
Materials And Methods
Our street medicine team distributed 200 naloxone kits accompanied by an educational training to a
convenience sample of adult clinicians involved in street outreach, as well as to a convenience sample of
volunteers and ‘first responders’ in the shelters, soup kitchens, and street medicine clinic settings. All
participants were age ≥18 years. Those receiving naloxone kits also received an educational training on how
to safely use the medication to reverse a potentially fatal opioid overdose.
Community sites where the street medicine team engaged regularly with this vulnerable population were
offered the opportunity for training. All sites showed interest in the training program and the street
medicine team collaborated via email with the study research coordinators to establish a date and time for
the training. The individual sites notified their respective team members about the agreed upon training
time and location; participation of trainees was voluntary, not mandatory. On arrival at the scheduled
training time, potential participants were given a standard project information sheet and offered the
opportunity to voluntarily participate in the naloxone education session and self-administer a brief pre- and
post-survey. The training was provided by the two street medicine team physician assistants who led the
program. Although there were occasional exceptions in which training was performed by their personal
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volunteer time, the preponderance of educational time spent by the street medicine physician assistants was
woven into their workday, which is paid for by their hospital salaries.
The references cited in this article were utilized to guide the development of the training curriculum. The
training was provided via a PowerPoint slide presentation that was peer-reviewed prior to its use by an
addiction recovery specialist and a board-certified addiction medicine physician, both of whom volunteered
their time, and have extensive experience in delivering community naloxone training.
We administered a pre- and post-survey of 10 multiple choice questions on material covered in the
educational training. The pre- and post-survey questions were developed by the street medicine team.
Before its use in the study, the survey was also peer-reviewed by a certified recovery specialist and a board-
certified addiction medicine physician who volunteered their time. Survey scores (10 point maximum) were
compared to assess any change in the number of correct responses before and after the brief educational
intervention. The pre- and post-surveys were the same with the exception of optional demographic
questions that were added to the pre-survey (Appendix). The pre-survey was given to participants before
they received the educational training, and the post-survey was given after they received the training. A
research assistant assigned a four-digit code to each participant to ensure pre- and post-surveys could be
compared. The trained research assistant collected the paper surveys and entered the data into a password-
protected electronic database accessible only to designated study members. The training program was
provided using a laptop for the PowerPoint slide and was approximately 60 minutes in length.
Descriptive statistics were generated for the sample. Categorical variables were described using the
frequency and percentage, and continuous variables were described using the mean, standard deviation,
median, and interquartile ranges as appropriate. By author convention, the pre-and post-survey data was
also stratified by gender and age group to determine any influence of these demographics on survey results.
To compare pre-education test scores to post-education test scores, the number of correct questions were
summed for each test by participant, and a paired t-test was used to determine if there was a statistically
significant change in the number of correct answers. All analyses were two-tailed and alpha was set to
significance at 0.05. SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was used to conduct the analysis.
The data for this study was stored and maintained in Research Electronic Data Capture (REDCap). REDCap is
a secure, web-based software platform designed to support data capture for research studies [21,22].
REDCap is installed directly on our institutional servers and is only accessible to individuals with an
institutional REDCap account. While potentially sensitive information such as age, gender, and
improvement in the number of correct survey questions was collected in the database, only those individuals
listed as investigators for the study had access to it. Data exported from this database was placed in a
password-protected spreadsheet for purposes of statistical analysis. This study was approved by the hospital
network institutional review board.
This study was funded, in part, by an unrestricted community foundation research and development award
for transformational excellence. The grant supported the naloxone purchase and research assistant time.
Results
A total of 200 survey participants were included. Six participants were excluded due to missing responses to
the pre-survey, post-survey or both pre- and post-survey questions. These six included two participants who
‘opted out’ of participation leaving 194 subjects included in the analysis. Demographics of the study
participants and their training location can be found in Table 1.
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 Total sample (n=194) Male (n=62) Female (n=120)
Training location    
Ripple Community Inc. 19 (9.8) 6 (9.7) 13 (10.8)
Safe Harbor Shelter 2 (1.0) 0 2 (1.7)
Trinity Soup Kitchen 7 (3.6) 4 (6.5) 3 (2.5)
Alliance Hall Soup Kitchen 4 (2.1) 1 (1.6) 2 (1.7)
Bethlehem Emergency Shelter 6 (3.1) 5 (8.1) 1 (0.8)
Allentown Warming Station 40 (20.6) 21 (33.9) 19 (15.8)
Bethlehem Recovery Center 17 (8.8) 4 (6.5) 13 (10.8)
Community Action Committee 25 (12.9) 5 (8.1) 15 (12.5)
Change on 3rd Street 17 (8.8) 8 (12.9) 8 (6.7)
Salvation Army 11 (5.7) 2 (3.2) 7 (5.8)
Highmark 7 (3.6) 2 (3.2) 3 (2.5)
School of Nursing 6 (3.1) 0 6 (5.0)
Family Health Center 16 (8.3) 1 (1.6) 14 (11.7)
Valley Health Partners 7 (3.6) 1 (1.6) 6 (5.0)
Other 10 (5.2) 2 (3.2) 8 (6.7)
Age, years (n=138), mean±SD 40.2±12.5 43.1±12.4 38.8±12.5
Age category (n=138) (n=138) (n=48) (n=88)
20-29 29 (21.0) 7 (14.6) 21 (23.9)
30-39 46 (33.3) 14 (29.2) 31 (35.2)
40-49 27 (19.6) 7 (14.6) 20 (22.7)
50-59 23 (16.7) 16 (33.3) 7 (8.0)
60-69 11 (8.0) 4 (8.3) 7 (8.0)
70+ 2 (1.5) 0 2 (2.3)
TABLE 1: Demographics for the entire sample and stratified by gender (n=194)
SD=standard deviation.
Data are expressed as n (%) unless otherwise stated. Percentages might not add to 100% due to rounding. If a training location was written under
‘Other’ with a frequency of >3, this location was then created as a new training location category (e.g., School of Nursing).
Not every participant responded to all survey questions. The number of responses for each question, for
each survey, can be found in Table 2.
 Pre-survey Post-survey
1. All opioids (e.g., fentanyl, heroin, prescription pain pills) have the potential to cause physical dependence. (n=193) (n=191)
True 191 (99.0) 190 (99.5)
False 2 (1.0) 1 (0.5)
2. What is the leading cause of injury-related death in the United States? (n=191) (n=191)
Alcohol overdose 15 (7.9) 3 (1.6)
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Falls 7 (3.7) 1 (0.5)
Fire/burn 1 (0.5) 0
Motor vehicle crashes 41 (21.5) 2 (1.1)
Opioid overdose 127 (66.5) 185 (96.9)
3. What cause(s) a person to be at a higher risk of an opioid overdose? (n=192) (n=194)
Having a medical condition such as HIV, liver, or lung disease 0 1 (0.5)
Taking higher doses of an opioid 5 (2.6) 3 (1.6)
Taking opioids with other sedating substances 5 (2.6) 1 (0.5)
Taking opioids after reduced tolerance (detox or incarceration) 6 (3.1) 1 (0.5)
All of the above 176 (91.7) 188 (96.9)
4. What is a symptom(s) of an opioid high? (n=192) (n=194)
Blue fingernails or lips 1 (0.5) 1 (0.5)
Constricted pupils 37 (19.3) 42 (21.7)
Gurgling 1 (0.5) 0
Unresponsive 8 (4.2) 1 (0.5)
All of the above 145 (75.5) 150 (77.3)
5. What’s the first step in managing a suspected opioid overdose? (n=191) (n=193)
Begin rescue breathing 6 (3.1) 1 (0.5)
Call 911 110 (57.6) 181 (93.8)
Give naloxone intra-nasally 45 (23.6) 6 (3.1)
Lay person in recovery position 15 (7.9) 1 (0.5)
Lay person on back 15 (7.9) 4 (2.1)
6. Administration of naloxone should be continued every minute until patient is revived. (n=183) (n=191)
True 51 (27.9) 7 (3.7)
False 132 (72.1) 184 (96.3)
7. After the initial administration of naloxone, what is the next step? (n=184) (n=193)
Begin hands-only cardiopulmonary resuscitation (CPR) 33 (17.9) 6 (3.1)
Call 911 54 (29.4) 14 (7.3)
Do not leave person 21 (11.4) 8 (4.2)
Head tilt/jaw-thrust 12 (6.5) 12 (6.2)
Lay person in recovery position 64 (34.8) 153 (79.3)
8. Which symptom(s) is indicative of opioid withdrawal? (n=191) (n=193)
Body aches 20 (10.5) 40 (20.7)
Dry skin 2 (1.1) 0
Chest pain 0 2 (1.0)
Sluggishness 2 (1.1) 5 (2.6)
All of the above 167 (87.4) 146 (75.7)
9. Narcan is effective for reversing which of the following overdoses? (n=181) (n=187)
Benzodiazepines 28 (15.5) 9 (4.8)
Cocaine 11 (6.1) 2 (1.1)
2021 Beauchamp et al. Cureus 13(11): e19831. DOI 10.7759/cureus.19831 5 of 11
Fentanyl 111 (61.3) 167 (89.3)
K2 2 (1.1) 2 (1.1)
Methamphetamine 29 (16.0) 7 (3.7)
10. The Good Samaritan Law only protects lay persons when responding to an opioid overdose and does not provide the person seeking medical attention after an overdose immunity from arrest. (n=187) (n=190)
True 95 (50.8) 69 (36.3)
False 92 (49.2) 121 (63.7)
Total score (range 0-10), mean±SD 5.5±1.6 7.5±1.3
TABLE 2: Pre- and post-survey questions for the entire sample (n=194)
SD=standard deviation.
Data are expressed as n (%) unless otherwise stated. Percentages might not add to 100% due to rounding. Some participants were noted to have circled
multiple answers; due to the nature of data collection and because only one answer could be selected, these participants were considered to have a
missing answer and were also counted as incorrect. Correct answers and n (%) for those are bolded.
Every survey question saw an increase in correct responses from pre-survey to post-survey (identified by an
increase in the percentage of correct responses). The mean total score increased from 5.5±1.6 to 7.5±1.3.
Within the sample of 194, the mean difference in scores from pre-survey to post-survey was 2.02 points (95%
CI [1.77, 2.26]); this finding was statistically significant (p<0.0001).
Males had a mean increase in the total score from 5.6±1.8 to 7.4±1.1. In the female sub-group, all survey
questions had an increase in the percentage of participants who chose the correct answer response, with a
mean increase in the total score from 5.5±1.5 to 7.5±1.3. There were no statistically significant differences
found in pre-survey scores, post-survey scores, or difference in total scores between males and females. A
comparison of mean pre- and post-survey scores by age group can be found in Figure 1.
FIGURE 1: Median pre- and post-survey scores by age group
Discussion
This study demonstrated that a brief educational presentation regarding naloxone, opioids, and overdose,
resulted in an increase in correct post-intervention survey responses regardless of the participant age or sex.
This study contributes to the literature by highlighting the effectiveness of implementing a brief educational
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intervention to accompany naloxone kit distribution to a small sample of people caring for individuals
experiencing homelessness.
We were able to successfully provide the educational training at over 15 different types of sites (soup
kitchens, shelters, etc). The number of the participants at each site was too small to do a statistical
comparison or sub-analysis for performance on the pre-/post-tests by site. This is an opportunity for future
research to glean a better understanding of how site-specific differences could impact the results.
Additionally, there were variations in the frequency of correct responses for individual questions. There
were some that most people got right and a few that appear to have been poorly understood before the
training. For instance, while nearly everyone understood that opioids could be addictive, their lethality or
how to recognize and intervene effectively for an overdose victim were not as universally comprehended.
This underscores the need for public health interventions and education of our community in this regard.
Some studies evaluating naloxone education focus on participants with a history of opioid use. Barocas et al.
found that of 543 opioid users, 33% reported having previously administered naloxone to an overdose
patient [23]. Wakeman et al. found that of 137 previous opioid users, 90% had willingness to undergo a two-
hour training for naloxone use [24]. Tobin et al. found similar results in a study design that included
naloxone education with pre- and post-test and administration of a take-home naloxone kit. Of the 85 prior
opioid users, 43 subsequently witnessed an overdose; 19 of the 43 were able to provide naloxone to the
patient successfully [25]. We were unable to extrapolate from such studies whether street outreach
volunteers would be as successful at administering naloxone as those who have lived experience with opioid
use or naloxone administration. One limitation of our study is that we did not survey participants regarding
any lived experience with opioid use or managing opioid overdose with naloxone. Additionally, our sample
was a convenience sample of those present and willing to participate at the designated sites. While all but
two of those who attended did elect to have their data included in the results (participated), the
characteristics of those volunteers at individual sites who did not elect to attend the training are not known.
The study design did not capture how many at each site were invited versus those who attended. The
potential selection bias this might have on the study findings is not known.
Another limitation of our study was that we did not track participant use of naloxone following the training.
We also did not assess participant concerns about naloxone administration, such as fears around
repercussions of providing naloxone. Evans et al. found that of 198 participants in a naloxone training, only
45.5% understood the Good Samaritan Law, which offers legal protection to those providing immediate
assistance to persons in danger [26]. We did not elicit feedback from the participants regarding their
satisfaction or potential areas of improvement for the training.
Future studies could explore post-training utilization of naloxone by participants, retention of knowledge
from the training, and outcomes in overdose victims receiving naloxone by study participants. Study design
may also be improved by expanding the educational intervention by including hands-on training using a
simulator mannequin. Surveying participants regarding barriers to naloxone use and addressing these
concerns could also improve educational interventions around naloxone administration. Finally, to address
the study limitation that we did not compare retention of knowledge by type of study site (street medicine
clinic versus shelter versus soup kitchen), we could design a larger study with matched numbers of
participants by training location type, and could also assess additional contributing factors such as
educational background, and whether the participant had any prior medical training.
This data will be used to further improve naloxone education delivery to street medicine volunteers, and
other street outreach team members in the community. Thus, this pilot project laid the groundwork for
ongoing naloxone training. Following the completion of this study, the street medicine team continues to
provide naloxone trainings at various sites that provide care to individuals experiencing homelessness. The
cost of naloxone is now covered by county drug and alcohol funding. This study will help secure ongoing
county funding for naloxone kits to be distributed to clinicians and volunteers who care for underserved
high-risk populations such as people experiencing homelessness.
Conclusions
In our study, the distribution of naloxone kits accompanied by an educational training addressing opioid
overdose and naloxone administration was performed. Pre- and post-survey comparisons indicated
improvement in responses across all age groups and by gender. Our findings give an example of how
communities can use resources to effectively disseminate naloxone education and medication kits that serve
high-risk community members such as those experiencing homelessness and substance use disorder.
Appendices
Pre/Post Community Narcan Training Test
Code: ______________________________________________________
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Age:
Gender (circle one):       Male       Female       Transgender       Nonbinary
 





Alliance Hall Soup Kitchen
Bethlehem Emergency Shelter
Allentown Warming Station
Other (please specify): ___________________________
 
1. True or false.
All opioids (e.g. Fentanyl, heroin, prescription pain pills) have the potential to cause physical dependence.
2. What is the leading cause of injury-related death in the United States?
a.       Alcohol overdose
b.       Falls
c.       Fire/burn
d.       Motor vehicle crashes
e.       Opioid overdose
3. What cause(s) a person to be at higher risk of an opioid overdose?
a.       Having a medical condition such as HIV, liver or lung disease
b.       Taking higher doses of an opioid
c.       Taking opioids with other sedating substances
d.       Taking opioids after reduced tolerance (detox or incarceration)
e.       All of the above
4. What is a symptom(s) of an opioid high?
a.       Blue fingernails or lips
b.       Constricted pupils
c.       Gurgling
d.       Unresponsive
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e.       All of the above
5. What’s the first step in managing a suspected opioid overdose?
a.       Begin rescue breathing
b.       Call 911
c.       Give naloxone intra-nasally
d.       Lay person in recovery position
e.       Lay person on back
6. True or false.
Administration of naloxone should be continued every minute until patient is revived.
7. After the initial administration of naloxone, what is the next step?
a.       Begin hands-only cardiopulmonary resuscitation (CPR)
b.       Call 911
c.       Do not leave person
d.       Head tilt/jaw-thrust
e.       Lay person in recovery position
8. Which symptom(s) is indicative of opioid withdrawal?
a.       Body aches
b.       Dry skin
c.       Chest pain
d.       Sluggishness
e.       All of the above
9. Narcan is effective for reversing which of the following overdoses?
a.       Benzodiazepines
b.       Cocaine
c.       Fentanyl
d.       K2
e.       Methamphetamine
10. True or false.
The Good Samaritan Law only protects lay persons when responding to an opioid overdose and does not
provide the person seeking medical attention after an overdose immunity from arrest.
Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Lehigh Valley Health
Network IRB issued approval STUDY00000289. Approval of Submission October 15, 2019 IRB00001409
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(IRB1) registered under FWA #00000624 MOD00001027 made changes to the design of the project, thereby
making it human subjects research. The designated reviewer reviewed and approved MOD00001027, and
determined the study to meet Exempt Category 2. Since MOD00001027 was approved by the designated
reviewer, the IRB staff completed the designated review on the main study dashboard, to transition
STUDY00000289 from “Not Human Research” to an approved human research project. Animal subjects: All
authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In
compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services
info: This study was funded, in part, by an unrestricted grant from a community foundation, the Dorothy
Rider Pool Health Care Trust Research and Development Award for Transformational Excellence. Financial
relationships: All authors have declared that they have no financial relationships at present or within the
previous three years with any organizations that might have an interest in the submitted work. Other
relationships: All authors have declared that there are no other relationships or activities that could appear
to have influenced the submitted work.
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